“`html
NK Cell Therapy Clinical Trials Analysis: Key Insights Into Rich Pipeline
Table of Contents
A new report highlights teh growing field of natural killer (NK) cell therapies, detailing over 160 potential treatments in development for various cancers and other diseases.
A new report titled, “NK Cell therapies Pipeline Insight, 2025” offers an in-depth analysis of the natural killer (NK) cell therapy landscape, including over 160 drugs in the pipeline. The report examines clinical and preclinical stage products, therapeutic assessments by product type, route of governance, and molecule type. It also identifies inactive pipeline products.
The study highlights companies developing therapies, such as Amgen, Innate Pharma, and ImmunityBio. These firms are exploring NK cell therapies for various conditions, including different types of cancer.
Key Developments in NK Cell Therapy
Recent activity in the NK cell therapy field includes:
- In June 2025, Artiva Biotherapeutics Inc. announced a Phase 2a study to assess AlloNK, an allogeneic cord blood-derived NK cell therapy, combined with rituximab for relapsing B-cell dependent rheumatologic diseases.
- The report identifies over 140 active companies developing more than 160 pipeline therapies.
“The report identifies over 140 active companies developing more than 160 pipeline therapies.”
Spotlight on oNKord and KUR-501
The report mentions specific NK cell therapies in development:
- oNKord: Glycostem Therapeutics is developing oNKord, an allogeneic NK cell therapy, using stem cells from healthy donors. Glycostem claims oNKord is highly reliable and reproducible and can potentially treat multiple myeloma,hematological cancers,and solid tumors like colorectal,head and neck,lung,and breast cancers. oNKord is currently in Phase I/II clinical trials for acute myeloid leukemia (AML).
- KUR-501: Athenex is developing KUR-501, an autologous cell therapy using Cell Medica’s natural killer T (NKT) cell platform. This therapy combines genetically engineered chimeric antigen receptors (CARs) and IL-15 cytokine secretion to sustain therapeutic cell activity within the tumor microenvironment. KUR-501, specifically CAR.GD2-IL-15 NKTs,targets GD2,a molecule found on neuroblastoma cells. The therapy is in a Phase I trial with Baylor College of Medicine (BCM) for pediatric neuroblastoma.
Frequently Asked Questions
- What are NK cells?
- NK cells are a type of immune cell that can kill infected or cancerous cells without prior sensitization.
- What is NK cell therapy?
- NK cell therapy involves using NK cells to treat diseases, particularly cancer. This can involve using a patient’s own NK cells or NK cells from a donor.
- What are the potential applications of NK cell therapy?
- NK cell therapy is being explored for various cancers, viral infections, and autoimmune diseases.
